Therapeutic drug monitoring in HIV infection: current status and future directions.
about
Therapeutic drug monitoring of antiretrovirals for people with HIVPlasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western TanzaniaLamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in ChinaPharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in IndiaPractical and conceptual challenges in measuring antiretroviral adherence.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patientsLack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylateBenefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trialThe role of clinical pharmacology in optimizing antiretroviral therapy.Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosinePharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant womenVariability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.Pharmacologic perspectives for once-daily antiretroviral therapy.Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practiceEstimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDSDrug interactions between proton pump inhibitors and antiretroviral drugs.HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsComparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina.Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adultsTherapeutic drug monitoring in highly active antiretroviral therapy.Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection.Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patientsPharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV.Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice.Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
P2860
Q24239932-D474325B-07E0-40E6-A841-936F93A9E79AQ28533168-1F333A28-88BA-46B6-8A6F-C61768BD6108Q28551633-48B6AAEF-33F5-4B04-B1C9-7B2F94BC1A0CQ33559015-046D3145-2114-4F2E-A7A2-2CBFC9FC1C3DQ33785839-25E74DE0-675C-40FE-AC26-958BF53A8CB2Q33835857-D2969B89-DE93-4CDF-9130-5B62EAC6734DQ33914723-92506291-D08E-41A6-92DD-31678EE10F06Q33927106-D06BED18-B86E-4C4C-985B-BE6A84F8C927Q34077060-7E27DE66-6025-4AFA-BE60-8DB2F463BA29Q34103495-53F995E6-E9F2-4B03-80EB-8456FA28566EQ35130818-D2A18C52-D9D0-4395-B538-DFE832A938DFQ35547290-ACBFBC30-6AAE-4E09-9E7E-DA6C30AE2E54Q35636071-5D1F30EA-E667-48DE-9298-145028B7A74EQ35827870-67A32F79-E4C3-4480-A54A-15693E5CD2B6Q35915916-6BEA4955-DB96-4698-B4C3-96E05D8058B5Q36024483-E0529DA4-DA4A-4D0E-8194-9A820910CA57Q36238198-8336DA25-783B-4030-96EF-4D73461D9380Q36277913-1487D458-18DE-426C-9934-7BD5BE7A7F93Q36336929-44353656-2F26-4F2D-AFA5-8D981D3BB38AQ36376533-6C7475D6-2D44-4D79-A31D-A133E351B2C0Q36544977-8F61365C-842D-4D10-BC4D-E8FA3C6B6250Q36683435-EB461A02-973D-4348-B1E1-47217C7425DCQ36708715-37451211-97AD-4672-8366-41CF7F3CA82FQ36788409-0154FFFE-61BF-4DC9-9769-AAC392C41998Q36877910-AFF27E7A-ADA8-450A-8CE5-74DB6FC74C29Q37199040-BC0860A4-343C-4C48-B4E5-F34B111D0F01Q37268002-CE3706DB-E3DC-4426-97DA-DEB746604CBCQ37598597-66091E44-97EE-4E36-A4C0-A0559E8DADFBQ37720765-AA3598EA-ADBC-40B2-94CC-D48262127638Q38086335-584A206A-BAA4-4BDA-80B7-DF219E0F6581Q38213320-9863B21E-686A-4BFE-AAD1-2F5B97AA3B49Q38377051-D399771D-B9F3-42CC-9329-0E2E74D562BEQ41021229-83E012FA-12D2-4F3F-ACD9-656F4F093461Q41906771-B2F22F54-4121-441E-96AE-F03CDDC74888Q41910769-615F5862-0A9B-4678-B9BF-E5A99C50BC2AQ42248475-A163C886-D525-4C08-922F-62A04CEDFB43Q43469365-32B59973-7668-442E-9BF8-85FC054A25B0Q45255502-A136D347-F8B3-4D07-AD55-05295D001C12Q45722783-0C7EF61A-FDCC-4C43-B76B-E0408570B747Q46504597-F4A4E8DF-2317-4352-85B9-65F3C8D59B2D
P2860
Therapeutic drug monitoring in HIV infection: current status and future directions.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Therapeutic drug monitoring in HIV infection: current status and future directions.
@ast
Therapeutic drug monitoring in HIV infection: current status and future directions.
@en
Therapeutic drug monitoring in HIV infection: current status and future directions.
@nl
type
label
Therapeutic drug monitoring in HIV infection: current status and future directions.
@ast
Therapeutic drug monitoring in HIV infection: current status and future directions.
@en
Therapeutic drug monitoring in HIV infection: current status and future directions.
@nl
prefLabel
Therapeutic drug monitoring in HIV infection: current status and future directions.
@ast
Therapeutic drug monitoring in HIV infection: current status and future directions.
@en
Therapeutic drug monitoring in HIV infection: current status and future directions.
@nl
P2093
P1433
P1476
Therapeutic drug monitoring in HIV infection: current status and future directions.
@en
P2093
Andrew Luber
Carlo-Federico Perno
Concepta Merry
Courtney Fletcher
David Back
Giorgio Gatti
Michael Kurowski
Richard Haubrich
Richard Hoetelmans
Rodolphe Garaffo
P356
10.1097/00002030-200203001-00002
P407
P478
16 Suppl 1
P577
2002-03-01T00:00:00Z